Scarica l'app Stockscreener
4.52
5.64%
-0.27
Precedente Chiudi:
$4.79
Aprire:
$4.77
Volume 24 ore:
200.94K
Relative Volume:
0.95
Capitalizzazione di mercato:
$94.03M
Reddito:
-
Utile/perdita netta:
$-117.17M
Rapporto P/E:
-0.3897
EPS:
-11.6
Flusso di cassa netto:
$-91.71M
1 W Prestazione:
-5.83%
1M Prestazione:
-22.74%
6M Prestazione:
-39.49%
1 anno Prestazione:
-50.87%
Intervallo 1D:
$4.445
$4.83
Intervallo di 1 settimana:
$4.445
$5.1098
Portata 52W:
$4.42
$29.70
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Nome
Adverum Biotechnologies Inc
Settore
Industria
Telefono
(650) 649-1004
Indirizzo
100 CARDINAL WAY, REDWOOD CITY, CA
Confronta ADVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
4.52 | 94.03M | 0 | -117.17M | -91.71M | -11.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Aggiornamento | Truist | Hold → Buy |
| 2021-07-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Downgrade | Truist | Buy → Hold |
| 2020-12-16 | Iniziato | UBS | Neutral |
| 2020-11-12 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-05 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-28 | Iniziato | Goldman | Buy |
| 2020-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-09-13 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-06-14 | Ripresa | Raymond James | Mkt Perform |
| 2018-11-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Downgrade | SunTrust | Buy → Hold |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Iniziato | SunTrust | Buy |
| 2018-02-15 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Target Price at $27.83 - Defense World
Geode Capital Management LLC Sells 16,731 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Barclays PLC Purchases 19,965 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
State Street Corp Boosts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Increase in Short Interest - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Large Increase in Short Interest - MarketBeat
Adverum Biotechnologies stock hits 52-week low at $4.61 - Investing.com
Adverum Biotechnologies (NASDAQ:ADVM) Cut to Sell at StockNews.com - Defense World
StockNews.com Downgrades Adverum Biotechnologies (NASDAQ:ADVM) to Sell - MarketBeat
Where are the Opportunities in (ADVM) - Stock Traders Daily
Fmr LLC Lowers Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Sold by Fmr LLC - MarketBeat
Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 - Marketscreener.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 11.1% in November - MarketBeat
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Drops By 11.1% - Defense World
ADVM stock touches 52-week low at $5.61 amid market challenges - Investing.com
StockNews.com Upgrades Adverum Biotechnologies (NASDAQ:ADVM) to Hold - Defense World
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) PT at $27.83 - MarketBeat
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Awards Key Talent Inducement Grants, Strengthens Team with Strategic Equity Package - StockTitan
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Biotechnologies Grants 55,000 Share Stock Option Package to New Employee | ADVM Stock News - StockTitan
Thinking about buying stock in Adverum Biotechnologies, Roma Gre - GuruFocus.com
Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director - Business Wire
Adverum Biotechnologies (NASDAQ:ADVM) Receives Buy Rating from HC Wainwright - MarketBeat
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients (NASDAQ:ADVM) - Seeking Alpha
Adverum Biotechnologies Announces Positive 52-Week LUNA and - GlobeNewswire
Adverum Biotechnologies, Inc. Announces Positive 52-Week Luna and 4-Year Optic Results, and Provides Key Pivotal Program Design Elements - Marketscreener.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 5.9% in October - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Adverum to present gene therapy data for eye disease - Investing.com India
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - The Manila Times
Adverum to present gene therapy data for eye disease By Investing.com - Investing.com UK
Adverum Biotechnologies Announces Webcast to Report 52-Week - GlobeNewswire
Logos Global Management LP Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
FMR LLC Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is BML Capital Management LLC's 6th Largest Position - MarketBeat
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles By Investing.com - Investing.com Nigeria
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles - Investing.com India
FY2024 Earnings Forecast for ADVM Issued By Chardan Capital - MarketBeat
HC Wainwright Issues Pessimistic Forecast for ADVM Earnings - Defense World
Morgan Stanley's Strategic Reduction in Adverum Biotechnologies Inc Shares - GuruFocus.com
(ADVM) Trading Advice - Stock Traders Daily
Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of Canada - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Posts Earnings Results - MarketBeat
Adverum Biotechnologies Advances in Gene Therapy Development - TipRanks
Adverum Biotechnologies Reports Third Quarter 2024 - GlobeNewswire
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Adverum Biotechnologies: Q3 Earnings Snapshot - San Antonio Express-News
Adverum Biotechnologies Inc Azioni (ADVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):